Omission of surgery in older women with early breast cancer has an adverse impact on breast cancer‐specific survival. BJS 2018; 105: 1454-1463.
Published: 22nd May 2018
Authors: S. E. Ward, P. D. Richards, J. L. Morgan, G. R. Holmes, J. W. Broggio, K. Collins et al.
Primary endocrine therapy is used as an alternative to surgery in up to 40 per cent of women with early breast cancer aged over 70 years in the UK. This study investigated the impact of surgery
Cancer registration data for 2002–2010 were obtained from two English regions. A retrospective analysis was performed for women with oestrogen receptor (ER)‐positive disease, using statistical modelling to show the effect of treatment (surgery or primary endocrine therapy) and age and health status on BCSS. Missing data were handled using multiple imputation.
Cancer registration data on 23 961 women were retrieved. After data preprocessing, 18 730 of 23 849 women (78·5 per cent) were identified as having ER‐positive disease; of these, 10 087 (53·9 per cent) had surgery and 8643 (46·1 per cent) had primary endocrine therapy. BCSS was worse in the primary endocrine therapy group than in the surgical group (5‐year BCSS rate 69·4 and 89·9 per cent respectively). This was true for all strata considered, although the difference was less in the cohort with the greatest degree of co‐morbidity. For older, frailer patients the hazard of breast cancer death had less relative impact on overall survival.
BCSS in older women with ER‐positive disease is worse if surgery is omitted. This treatment choice may contribute to inferior cancer outcomes. Selection for surgery on the basis of predicted life expectancy may permit choice of women for whom surgery confers little benefit.Full text
You may also be interested in
Randomized clinical trial
INTEND II randomized clinical trial of intraoperative duct endoscopy in pathological nipple discharge.
Authors: G. Gui, A. Agusti, D. Twelves, S. Tang, M. Kabir, C. Montgomery et al.
Notes: Identifies causative lesion
Aesthetic outcome following breast‐conserving surgery assessed by three evaluation modalities in relation to health‐related quality of life.
Authors: C. Dahlbäck, A. Ringberg, J. Manjer
Notes: Better methods needed
Current practice and short‐term outcomes of therapeutic mammaplasty in the international TeaM multicentre prospective cohort study.
Authors: R. L. O'Connell, E. Baker, A. Trickey, T. Rattay, L. Whisker, R. D. Macmillan et al.
Notes: Reduces mastectomy rates
Nationwide population‐based study of trends and regional variation in breast‐conserving treatment for breast cancer.
Authors: M. C. van Maaren, L. J. A. Strobbe, L. B. Koppert, P. M. P. Poortmans, S. Siesling
Notes: Regional differences remain
Survival and risk of breast cancer recurrence after breast reconstruction with deep inferior epigastric perforator flap. BJS 2018; 105: 1446-1453.
Authors: A. Svee, M. Mani, K. Sandquist, T. Audolfsson, Y. Folkvaljon, A. E. Isern et al.
Authors: N. Patani, F. MacAskill, S. Eshelby, A. Omar, A. Kaura, K. Contractor et al.
Notes: Outcomes improve
Meta‐analysis of the cumulative risk of endometrial malignancy and systematic review of endometrial surveillance in extended tamoxifen therapy. BJS 2018; 105: 1098-1106.
Authors: C. A. Fleming, H. M. Heneghan, D. O'Brien, D. P. McCartan, E. W. McDermott, R. S. Prichard et al.
Notes: Counselling of patients important
Meta‐analysis of the diagnostic accuracy of ultrasound‐guided fine‐needle aspiration and core needle biopsy in diagnosing axillary lymph node metastasis. BJS 2018; 105: 1244-1253.
Authors: I. Balasubramanian, C. A. Fleming, M. A. Corrigan, H. P. Redmond, M. J. Kerin, A. J. Lowery et al.
Notes: Core needle biopsy better
Breast‐conserving surgery followed by whole‐breast irradiation offers survival benefits over mastectomy without irradiation.
Authors: J. de Boniface, J. Frisell, L. Bergkvist, Y. Andersson
Notes: RT to lower axilla key?
Is axillary ultrasound imaging necessary for all patients with breast cancer?. BJS 2018; 105: 930-932.
Authors: M. Ahmed, M. Douek
Meta‐analysis of the oncological safety of autologous fat transfer after breast cancer. BJS 2018; 105: 1082-1097.
Authors: T. K. Krastev, S. J. Schop, J. Hommes, A. A. Piatkowski, E. M. Heuts, R. R. W. J. van der Hulst et al.
Notes: Lipofilling ok
Risk of recurrence and death in patients with breast cancer after delayed deep inferior epigastric perforator flap reconstruction. BJS 2018; 105: 1435-1445.
Authors: H. Adam, A. C. Docherty Skogh, Å. Edsander Nord, I. Schultz, J. Gahm, P. Hall et al.
Notes: Deep inferior epigastric perforator is safe